Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegfilgrastim - Amgen/Kyowa Kirin

Drug Profile

Pegfilgrastim - Amgen/Kyowa Kirin

Alternative Names: Filgrastim SD01; G-Lasta; KRN125; Neulasta; Neulasta Onpro® Kit; Neulastim; PEG filgrastim; PEG G-CSF; PEG-rmetHuG-CSF; Pegylated filgrastim; R 1471; r-metHuG-CSF-SD-01; SD-01; SD/01

Latest Information Update: 16 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kirin-Amgen
  • Developer Amgen; Kyowa Kirin
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neutropenia; Radiation injuries
  • Phase II Breast cancer

Most Recent Events

  • 28 May 2019 Kyowa Hakko Kirin initiates a phase II trial in volunteers in Japan (SC) (NCT03993639)
  • 20 Nov 2018 Kyowa Hakko Kirin plans a phase II trial for Neutropenia in South Korea (KCT0002985)
  • 01 Jul 2018 Phase-II clinical trials in Breast cancer (Neoadjuvant therapy, Combination therapy, Second-line therapy or greater) in France (SC) (NCT03571633)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top